Weekly influenza update, week 8, February 2018

data infographic map
Period: 19 Feb 2018 - 25 Feb 2018

Influenza activity was widespread in the majority of reporting countries. Overall, 49% of individuals sampled from primary healthcare settings tested positive for influenza virus, a slight decrease compared to the previous week (51%). Both influenza virus types A and B were co-circulating with a higher proportion of type B viruses. Differences in proportions of circulating influenza virus types and A subtypes were observed between countries. The majority of severe cases admitted to non-ICU hospital wards were adults infected by influenza type B viruses. Half of severe cases admitted to ICU were adults infected by influenza type A viruses. Based on data provided by 20 EU countries to EuroMOMO, excess mortality from all causes has elevated significantly over the past months in the south-western part of the European region, but this increase seems less in some countries.

Flu situation report week 8/2018 (19-25 February 2018)

2017/18 season overview 

  • For the region overall, a higher proportion of type B compared to type A viruses has been detected in sentinel and non-sentinel sources, representing a high level of circulation of influenza B viruses compared with previous seasons. Of the type A virus detections from sentinel sources, the majority of which were subtyped, A(H1N1)pdm09 viruses have outnumbered A(H3N2) viruses. In non-sentinel sources, more A(H3N2) viruses were reported than A(H1N1)pdm09 viruses.
  • The majority of severe cases reported this season are due to influenza B and occur in persons above the age of 15 years. In laboratory-confirmed influenza cases in ICU, comparable numbers were infected by influenza type A and B viruses, and the elderly were at increased risk of ICU admission. In laboratory-confirmed influenza cases reported from wards other than ICU, type B viruses were detected approximately twice as frequently as type A viruses.
  • For type B viruses from both sentinel and non-sentinel sources, B/Yamagata lineage viruses have greatly outnumbered those of the B/Victoria lineage. The current trivalent seasonal influenza vaccine does not include a virus from the B/Yamagata lineage.
  • Different patterns of dominant type and A subtypes were observed between the countries of the Region, which may be due to differences in relative weights of information being derived from sentinel, non-sentinel and severe influenza case sources of information.
  • Different patterns of dominant type and A subtype were observed between the countries of the Region, which may be due to differences in relative weights of information being derived from sentinel, non-sentinel and severe influenza case sources of information.
  • While low in number, 59% of the genetically characterized A(H3N2) viruses belong to clade 3C.2a, the clade of the vaccine virus described in the WHO recommendations for vaccine composition for the northern hemisphere 2017–2018, and 37% to subclade 3C.2a1, with mammalian cell-cultured viruses in both clades being antigenically similar.
  • Although few B/Victoria lineage viruses have been detected, their characterization has shown an increasing percentage (currently 47%) of viruses belonging to a subclade of clade 1A viruses, represented by B/Norway/2409/2017. These viruses have a two amino acid deletion in haemagglutinin (Δ162-163) and are antigenically different from the current trivalent vaccine component, a B/Brisbane/60/2008-like virus.
  • Interim or real-time vaccine effectiveness estimates from CanadaFinlandGermanySpainStockholm County and the United States of America suggest overall vaccine effectiveness of 15–46%, depending on the proportions of circulating (sub)types. Effectiveness against influenza B is in the range of 16–67%, despite the circulating lineage not being included in the most commonly used trivalent vaccine.
  • Additional information on global influenza activity is available from WHO’s biweekly global updates.
  • 19–21 February 2018, WHO-HQ convened the Vaccine Composition Meeting, which made recommendations for the composition of the 2018–2019 northern hemisphere vaccine. The full report is available here.

See all weekly influenza updates

Data

Weekly influenza update, week 19, May 2019

infographic -

Data

Weekly influenza update, week 18, May 2019

infographic -

Data

Weekly influenza update, week 17, April 2019

infographic -

Data

Weekly influenza update, week 16, April 2019

infographic -

Data

Weekly influenza update, week 15, April 2019

infographic -